ProCE Banner Activity

CME

AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

Video

Watch this on-demand webcast from a live symposium on therapeutic options for patients with AL amyloidosis, including discussions on diagnosis, efficacy and safety data, supportive care, and ongoing clinical trials.

Physicians: Maximum of 2.25 AMA PRA Category 1 Credits

Released: January 23, 2023

Expiration: January 22, 2024

No longer available for credit.

Share

Faculty

Anita D Souza

Anita D Souza, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Medical College of Wisconsin
Attending Physician
Froedtert & Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

Angela Dispenzieri

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Jeffrey Zonder

Jeffrey Zonder, MD

Professor of Oncology  
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Alexion Pharmaceuticals, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Alexion Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners in using novel therapeutic options for patients with AL amyloidosis.

Learning Objectives

  • Diagnose AL amyloidosis through timely and accurate typing of the precursor protein to guide specific management approaches
  • Integrate into practice up-to-date efficacy and safety data on currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
  • Plan evidence-based supportive therapy in AL amyloidosis to improve quality of life, relieve symptoms, and sustain organ function
  • Identify patients appropriate for enrollment on ongoing clinical trials evaluating novel therapy for the treatment of patients with AL amyloidosis

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Program Director Disclosure

Program Director

Angela Dispenzieri, MD

Consultant
Division of Hematology
Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine 
Mayo Clinic
Rochester, Minnesota 

Angela Dispenzieri, MD: consultant/advisor/speaker: Oncopeptides, Sorento; researcher: Alnylam, Bristol-Myers Squibb, Janssen, Pfizer, Takeda.

Faculty Disclosure

Primary Author

Anita D Souza, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Medical College of Wisconsin
Attending Physician
Froedtert & Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin

Anita D’Souza, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Janssen, Prothena; researcher: AbbVie, Caelum, Janssen, Prothena, Regeneron, Sanofi, Takeda, TeneoBio.

Jeffrey Zonder, MD

Professor of Oncology  
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Jeffrey Zonder, MD: consultant/advisor/speaker: Caelum/AstraZeneca, Intellia, Janssen, Prothena, Regeneron, Takeda; researcher: Bristol-Myers Squibb.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from January 23, 2023, through January 22, 2024:

  1. Create an account or Login at https://clinicaloptions.com/
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 23, 2023, through January 22, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.